Why Is argenx Stock Rallying Today? Celiac Disease Drug Data Helps Shares Recover
argenx stock is rebounding on October 9, 2026, after a sharp sell-off triggered by disappointing clinical-trial news. The biotech company’s shares rose as investors reassessed the scale of the setback, supported by positive results from a separate experimental drug and continued analyst support.
The recovery comes just one day after argenx SE announced that it was discontinuing a late-stage trial of efgartigimod, marketed as Vyvgart, in patients with Sjögren’s disease. The decision sent the stock sharply lower on October 8. On Friday, investors appeared to be weighing that disappointment against encouraging developments elsewhere in the company’s drug pipeline.
The main takeaway for investors is that argenx’s rally looks like a partial recovery after a major setback—not proof that the clinical risk has disappeared. The company still has important commercial assets and other experimental treatments, but the failed trial raises questions about how far its flagship drug can expand into new diseases.
Why Is argenx Stock Rising on October 9?
According to Investing.com, argenx shares were up approximately 4.7% at €738.60 in Friday trading. That followed a decline of roughly 15.9% on October 8, when the company announced the end of its Phase 3 UNITY study in Sjögren’s disease. The reported Friday move reflected a combination of bargain-hunting, analyst reassurance and positive news about another drug candidate.
Three factors are helping explain the rebound.
1. Positive Phase 2 results for experimental drug FB102
A key development is argenx’s announcement on October 8 that FB102 met the primary endpoint in a Phase 2 study involving adults with celiac disease.
The trial assessed whether the experimental treatment could protect the small intestine from gluten-induced damage. The company reported a statistically significant treatment effect compared with placebo on the primary measure of intestinal tissue structure, with a p-value of 0.0176. It also said other measures of inflammation and symptoms were consistent with the primary result.
The study enrolled 126 patients and evaluated FB102 during a controlled gluten challenge. Argenx plans to advance the candidate into Phase 3 development. The company also reported no new safety signals in the study.
For investors, this matters because biotech companies are often valued on both their current medicines and the potential of future treatments. Positive results from FB102 provide another possible source of long-term growth, helping offset some concern about the failed Sjögren’s trial.
There is an important caveat, however: FB102 remains investigational. A successful Phase 2 study does not guarantee success in Phase 3, regulatory approval or commercial sales. The next stages will need to confirm the treatment’s efficacy and safety in larger studies.
2. Investors are reassessing the scale of the Sjögren’s setback
The sharp decline on Thursday created the conditions for a rebound. After a large one-day fall, some investors may decide that the market has priced in too much bad news, while others may buy shares at lower levels in anticipation of a recovery.
That appears to be part of Friday’s move. It does not mean the original news has become less serious.
The independent data monitoring committee overseeing the UNITY study recommended stopping it after an interim analysis concluded that the trial was unlikely to meet its primary endpoint, which measured changes in systemic disease activity. Argenx said it would discontinue the study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren’s disease.
The failure is significant because Sjögren’s disease represents an area of unmet medical need. The condition is an autoimmune disorder that can damage the glands responsible for producing tears and saliva, and it can cause broader systemic symptoms. Analysts had viewed the trial as an opportunity to expand Vyvgart into another therapeutic area.
The result therefore removes one potential growth opportunity for the drug. The stock’s rebound reflects investors reassessing the impact on the company as a whole, rather than a reversal of the clinical outcome.
3. Analyst ratings and the broader market are providing support
Investing.com reported that Wedbush maintained an Outperform rating while trimming its price target, Bernstein issued a Buy rating, and Goldman Sachs retained its Buy stance while lowering its euro-denominated target. These positions suggest that some analysts continue to see value in argenx despite the trial failure.
Analyst ratings are not guarantees of future performance. Price targets depend on assumptions about sales, competition, clinical success and valuation, all of which can change quickly for biotechnology companies.
A more supportive European equity market also helped the shares recover on Friday, according to Investing.com. But the main drivers appear to be company-specific: the positive FB102 data, the reassessment of Thursday’s sell-off and investor attention to argenx’s remaining pipeline.
What Does the Trial Failure Mean for Vyvgart?
Vyvgart, the brand name for efgartigimod, is argenx’s flagship medicine and has been used to treat other autoimmune conditions. The company had been exploring whether the drug could also become a treatment option for Sjögren’s disease.
The failed UNITY study narrows that particular expansion opportunity. It may also prompt investors to reconsider how much future revenue they should attribute to additional uses of efgartigimod.
However, the result does not automatically invalidate the drug’s established role in other approved indications. Clinical results can differ across diseases because the underlying biology, patient populations and trial endpoints are not identical.
The distinction is important: the news is a setback for one proposed use of the medicine, not evidence that all of Vyvgart’s existing uses have failed.
For argenx, the commercial priority will remain growing its established business while determining how best to allocate resources across other potential treatments. Investors will want management to clarify whether the discontinued programme changes research spending, future development priorities or the company’s longer-term growth expectations.
What Should Investors Watch Next?
The immediate question is whether argenx can stabilise after the sharp sell-off. Beyond the next few trading sessions, several developments will matter more than a single day’s share-price recovery.
Further details on FB102: Full Phase 2 results, upcoming medical presentations and the design of the planned Phase 3 programme will help investors judge how robust the findings are.
Vyvgart’s performance in existing indications: Continued commercial growth would help demonstrate that the Sjögren’s setback is not undermining the wider business.
Other clinical programmes: Argenx has been developing efgartigimod for additional autoimmune conditions, including autoimmune myositis, where the company announced positive Phase 3 topline results in August 2026.
Management’s next update: Investors should look for commentary on the implications of the UNITY decision, future research priorities and the financial outlook. Argenx’s published financial calendar lists its third-quarter 2026 results and business update for October 22.
Share-price volatility: Clinical-trial announcements can move biotech stocks sharply in either direction. A rebound after a sell-off does not, on its own, establish a durable recovery.
For Indian investors following US-listed biotechnology stocks, currency movements and the costs of accessing overseas markets can also affect returns. The underlying clinical and commercial risks remain the central considerations.
The Bottom Line
argenx stock is rallying because investors are reassessing Thursday’s steep decline, while positive Phase 2 results for FB102 and continued analyst support offer reasons for cautious optimism. Yet the failed Phase 3 Sjögren’s study remains a material setback for the company’s plans to expand Vyvgart into another disease area.
The next test is whether argenx can translate its encouraging pipeline results into successful later-stage trials while continuing to grow its established medicines. Investors should focus on clinical evidence, commercial performance and management’s next update—not assume that one session of gains marks the end of the volatility.
Follow our blog for more updates on global stocks, biotechnology companies and important market developments.
Disclaimer: This article is for informational and educational purposes only and should not be considered investment advice.